within Pharmacolibrary.Drugs.R_RespiratorySystem.R01A_DecongestantsAndOtherNasalPreparationsForTopical.R01AA05_Oxymetazoline;

model Oxymetazoline
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 0,
    adminDuration = 600,
    adminMass = 0.05 / 1000000,
    adminCount = 1,
    Vd = 0.001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Oxymetazoline</td></tr><tr><td>ATC code:</td><td>R01AA05</td></tr><td>route:</td><td>intranasal</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.05</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0</td><td></td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Oxymetazoline is an imidazoline decongestant, primarily used as a topical nasal spray for temporary relief of nasal congestion due to common cold, hay fever, or allergies. It acts as an alpha-adrenergic agonist leading to vasoconstriction. Oxymetazoline is available in over-the-counter formulations and is still approved for use today.</p><h4>Pharmacokinetics</h4><p>There are very limited published data on the pharmacokinetic parameters of oxymetazoline in humans, especially after intranasal administration. No full pharmacokinetic profile with explicit parameters based on published population PK models is available in the literature.</p><h4>References</h4><ol><li><p>Cacek, AT, et al., &amp; Gopalakrishnan, M (2017). Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. <i>Journal of clinical pharmacology</i> 57(2) 247–254. DOI:<a href=\"https://doi.org/10.1002/jcph.799\">10.1002/jcph.799</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27436060/\">https://pubmed.ncbi.nlm.nih.gov/27436060</a></p></li><li><p>Kaessner, N, et al., &amp; Lahu, G (2012). Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain. <i>International journal of clinical pharmacology and therapeutics</i> 50(9) 665–677. DOI:<a href=\"https://doi.org/10.5414/CP201737\">10.5414/CP201737</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22784611/\">https://pubmed.ncbi.nlm.nih.gov/22784611</a></p></li><li><p>Cartabuke, RS, et al., &amp; Tobias, JD (2019). Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children. <i>The Laryngoscope</i> 129(12) 2775–2781. DOI:<a href=\"https://doi.org/10.1002/lary.27760\">10.1002/lary.27760</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30786035/\">https://pubmed.ncbi.nlm.nih.gov/30786035</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R01AA05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Oxymetazoline;
